• 1
    Aceijas C., Stimson G. V., Hickman M., Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 2004; 18: 22952303.
  • 2
    Mathers B. M., Degenhardt L., Phillips B., Wiessing L., Hickman M., Strathdee S. A. et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 17331745.
  • 3
    Degenhardt L., Bucello C., Calabria B., Nelson P., Roberts A., Hall W. et al. What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug Alcohol Depend 2011; 117: 85101.
  • 4
    King R., Bird S., Hay G., Hutchinson S. Estimating current injectors in Scotland and their drug-related death rate by sex, region and age-group via Bayesian capture–recapture methods. Stat Methods Med Res 2009; 18: 341359.
  • 5
    Hay G., Gannon M., Macdougall J., Eastwood C., Williams K., Millar T. Capture–recapture and anchored prevalence estimation of injecting drug users in England: national and regional estimates. Stat Methods Med Res 2009; 18: 323339.
  • 6
    Sweeting M. J., De Angelis D., Ades A. E., Hickman M. Estimating the prevalence of ex-injecting drug use in the population. Stat Methods Med Res 2009; 18: 381395.
  • 7
    Singleton N., Murray R., Tinsley L. Home Office Online Report 16[06]. 2006. London: Home Office.
  • 8
    Ades A. E., Welton N. J., Caldwell D., Price M., Goubar A., Lu G. Multiparameter evidence synthesis in epidemiology and medical decision-making. J Health Serv Res Policy 2008; 13: 1222.
  • 9
    Ades A. E., Sutton A. J. Multiple parameter evidence synthesis in epidemiology and medical decision making: current approaches. J R Stat Soc Ser A 2006; 169: 535.
  • 10
    Meader N. A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis. Drug Alcohol Depend 2010; 108: 110114.
  • 11
    Sutton A., Ades A. E., Cooper N., Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008; 26: 753767.
  • 12
    Ades A. E., Sculpher M., Sutton A., Abrams K., Cooper N., Welton N. et al. Bayesian methods for evidence synthesis in cost–effectiveness analysis. Pharmacoeconomics 2006; 24: 119.
  • 13
    Sweeting M. J., De Angelis D., Hickman M., Ades A. E. Estimating hepatitis C prevalence in England and Wales by synthesizing evidence from multiple data sources. Assessing data conflict and model fit. Biostatistics 2008; 9: 715734.
  • 14
    De Angelis D., Sweeting M., Ades A., Hickman M., Hope V., Ramsay M. An evidence synthesis approach to estimating hepatitis C prevalence in England and Wales. Stat Methods Med Res 2009; 18: 361379.
  • 15
    Harris R. J., Ramsay M., Hope V. D., Brant L., Hickman M., Foster G. R. et al. Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health 2012; 22: 187192.
  • 16
    Price M. J., Ades A. E., Welton N. J., Macleod J., Turner K., Simms I. et al. How much tubal factor infertility is caused by Chlamydia? Estimates based on serological evidence corrected for sensitivity and specificity. Sex Transm Dis 2012; 39: 608613.
  • 17
    Welton N., Ades A. E. A model of toxoplasmosis incidence in the UK: evidence synthesis and consistency of evidence. J R Stat Soc Ser C Appl Stat 2005; 54: 385404.
  • 18
    Goubar A., Ades A. E., De Angelis D., McGarrigle C., Mercer C., Tookey P. et al. Estimates of HIV prevalence and proportion diagnosed based on Bayesian multi-parameter synthesis of surveillance data. J R Stat Soc Ser A 2008; 171: 541580.
  • 19
    Presanis A. M., Gill O. N., Chadborn T. R., Hill C., Hope V., Logan L. et al. Insights into the rise in HIV infections, 2001 to 2008: a Bayesian synthesis of prevalence evidence. AIDS 2010; 24: 28492858.